There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cingulate Inc (CING – Research Report), Achieve Life Sciences (ACHV – Research Report) and Apellis Pharmaceuticals (APLS – Research Report) with bullish sentiments.
Cingulate Inc (CING)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Cingulate Inc. The company’s shares closed last Wednesday at $0.80, close to its 52-week low of $0.66.
According to TipRanks.com, Rahman is a 1-star analyst with an average return of
Currently, the analyst consensus on Cingulate Inc is a Moderate Buy with an average price target of $7.00.
See today’s best-performing stocks on TipRanks >>
Achieve Life Sciences (ACHV)
Maxim Group analyst Jason McCarthy reiterated a Buy rating on Achieve Life Sciences yesterday and set a price target of $20.00. The company’s shares closed last Wednesday at $5.55.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Achieve Life Sciences with a $24.67 average price target.
Apellis Pharmaceuticals (APLS)
In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Apellis Pharmaceuticals, with a price target of $114.00. The company’s shares closed last Wednesday at $85.01.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apellis Pharmaceuticals with a $104.54 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CING:
- Cingulate announces results from Phase 3 trial of CTx-1301
- Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
- Cingulate manufactures clinical supply, to initiate Phase 3 trials of CTx-1301
- Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
- Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
